Skip to main content
Top
Published in: Journal of Nephrology 4/2014

01-08-2014 | Letter to the Editor

Comment on Suzuki et al.: “Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy”

Author: Onur Sakallıoğlu

Published in: Journal of Nephrology | Issue 4/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
go back to reference Suzuki H, Ohsawa I, Kodama F et al (2013) Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. J Nephrol 26(4):708–715PubMedCrossRef Suzuki H, Ohsawa I, Kodama F et al (2013) Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. J Nephrol 26(4):708–715PubMedCrossRef
2.
go back to reference Mollnes TE, Jokiranta TS, Truedsson L et al (2007) Complement analysis in 21st century. Mol Immunol 44:3838–3849PubMedCrossRef Mollnes TE, Jokiranta TS, Truedsson L et al (2007) Complement analysis in 21st century. Mol Immunol 44:3838–3849PubMedCrossRef
Metadata
Title
Comment on Suzuki et al.: “Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy”
Author
Onur Sakallıoğlu
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 4/2014
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-014-0104-x

Other articles of this Issue 4/2014

Journal of Nephrology 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine